The objectives of this clinical trial are to compare the incidence and duration of air leaks and the incidence of prolonged air leaks (defined as > 5 days by the Society for Thoracic Surgery) when using the ENDO GIA™ Stapler with ENDO GIA™ SULU with TRI-STAPLE™ Technology in a pulmonary resection via Video Assisted Thoracoscopic Surgery (VATS).

Inclusion Criteria:

• The subject must be 18 years of age or older.
• The subject must be scheduled to undergo wedge resection or lobectomy via Video Assisted Thoracoscopic Surgery (VATS) for a lung nodule suspicious for or clinically proven to be primary lung cancer.
• The subject must be able to tolerate general anesthesia and have cardiopulmonary reserve to tolerate the procedure.
• The subject must be willing and able to comply with all study requirements and have understood and signed the informed consent.

Exclusion Criteria:

• The subject is pregnant or breastfeeding.
• The subject is scheduled to undergo sleeve lobectomy, segmentectomy, bi-lobectomy, pneumonectomy or Lung Volume Reduction Surgery (LVRS), or lung biopsy for suspected interstitial lung disease.
• A rib-spreading thoracotomy incision is scheduled to be performed, however the use of an access incision without rib-spreading for specimen removal or to facilitate hilar dissection is allowed. VATS procedures that are converted in the operating room to open procedures are not exclusionary.
• The subject has received pre-operative chemotherapy or radiation therapy for the lung cancer that will be resected.
• The subject is scheduled to receive intra-operative brachytherapy.
• The subject has other severe illnesses that would preclude surgery such as unstable angina or myocardial infarction within 3 months.
• Re-operative surgery is excluded if it is on the same side as the previous surgery.
• Investigator determines that participation in the study may jeopardize the safety or welfare of the subject.
• The subject is unable to comply with the follow-up visit schedule

128 subjects were screened for enrollment. 50 subjects were consented, enrolled and treated. There were 78 screen failures. 3 subjects were excluded from analysis, leaving 47 eligible subjects.

Adverse events were collected up to 30 days post surgery.